Pear Therapeutics — Investor Day (June 2022)
64 slides from Pear Therapeutics's investor day presentation, Jun 6, 2022
Slide 1: Software for the Treatment of Serious Disease: Investor Day
1 Software for the Treatment of Serious Disease Prescription Digital Therapeutics Investor Day June 6, 2022
Slide 2: Forward-Looking Statements and other Cautions
2 Forward-Looking Statements and other Cautions/Industry and Market Data Unless the context indicates otherwise, the terms “Pear,” “Company,” “we,” “us,” and “our” refer to Pear Therapeutics, Inc. This presentation contains forward-looking statements within the meaning of the safe harbor provisions
Slide 3: The Presenters
3 The Presenters VP, Government Affairs BETH KEYT VP, Market Access MARK HOPMAN MBA, RPH CEO COREY MCCANN MD, PHD CMO YURI MARICICH MD, MBA CCO JULIA STRANDBERG MBA
Slide 4: Agenda
4 Agenda Topic Time • Introduction to Pear Therapeutics 20 minutes • Medical: Clinical Data and Evidence 60 minutes • Market Access: Payment Infrastructure 60 minutes • Wrap Up 10 minutes
Slide 5: Pear is the category creator and leader in PDTs
5 Pear is the category creator and leader in Prescription Digital Therapeutics (PDTs) 1 4 Pear is the first mover and leader in PDTs via the first three FDA-authorized products P E A R I S A P I O N E E R FDA-authorized reSET®, reSET-O®, and Somryst® for the treatment of addiction and chronic insomn
Slide 6: Drivers of our functional metrics and recent milestones
6 Total Prescriptions3 Fulfillment Rate4 Payment Rate5 Average Selling Price (ASP)6 CPT Codes RECENT MILESTONES EHR Integration Real-World Health Economic Evidence State and Federal Legislation HCPCS Code Access Agreements Today’s discussion is focused on several drivers of our functional metrics
Slide 7: Data and evidence support the value proposition for PDTs
7 24/7 remote access without fear of stigma Favorable side effect profile vs medications Reduce overall healthcare costs Fill gaps in care across large populations Improve reach allowing for broader patient impact Reimbursable events for dashboard interactions 24/7 remote access without the fear of
Slide 8: Example data and evidence supporting reSET and reSET-O
8 Example data and evidence supporting reSET® and reSET-O® Patient and Clinician Payor ✓ Strong patient engagement7,8 ✓ Reduced substance use9 ✓ Enhanced retention in therapy9,10 ✓ High patient and clinician satisfaction11 ✓ Reduced inpatient hospitalizations12 ✓ Reduced emergency department use12 ✓
Slide 9: Dr. Scott Whittle, Former Medical Director, Intermountain Healthcare
9 Dr. Scott Whittle Former Medical Director Intermountain Healthcare
Slide 10: Emerging sector of software-based medicines
10 E M E R G I N G S E C T O R O F S O F T W A R E - B A S E D M E D I C I N E S We believe Prescription Digital Therapeutics (PDTs) could become first-line treatment for many conditions, disrupting the >$3T global healthcare industry1 P D T C A T E G O R Y C R E A T O R P O I S E D F O R M A S S I
Slide 11: Agenda
11 Agenda Topic Time • Introduction to Pear Therapeutics 20 minutes • Medical: Clinical Data and Evidence 60 minutes • Market Access: Payment Infrastructure 60 minutes • Wrap Up 10 minutes
Slide 12: Pear's first three commercial products address major medical conditions
12 N u m b e r o f P e o p l e w i t h D i s e a s e i n U S 1 , 2 ~30MOnly FDA-authorized drug-free and guideline- recommended treatment for chronic insomnia ~40MOnly product FDA-authorized to treat addiction to alcohol, cannabis, cocaine, and stimulants ~3M Only FDA-authorized software product tha
Slide 13: Data generation strategy: continuum of evidence
13 Our data generation strategy is proving that our products work for key stakeholders Randomized Controlled Trials (RCTs) Real-World Clinical Evidence Real-World Health Economic Evidence Demonstrate gold-standard scientific validity using objective endpoints Confirm generalizability of results in r
Slide 14: Products enable secure data aggregation
14 Pear’s products are designed to enable secure data aggregation to support patient access and outcomes Patient Clinician Payor • Engagement • Patient Reported Outcomes (PROs) • Clinical Outcomes • Population(s) Management • Clinician input data • Lab values • Claims data • Outcomes data • Populati
Slide 15: Products bolstered by significant clinical evidence
15 Randomized Controlled Trials Real World Clinical and Health Economic Data Number of Trials Number of Patients Duration Number of Publications Number of Patients Duration 2* >1,000 12 month 2 >700 6 month 3* >450 12 month 5 >6,900 6, 9, 12 month 44† (2 FDA pivotals) >5,000 36 month 2† >8,000 24 mo
Slide 16: Studies include underserved populations
16 Studies supporting Pear’s PDTs include underserved populations Inclusion of females (>30%) ✓3,4,59-64 ✓7,9,10,11,12,65 ✓15,16,21,23,24,27,28,67,68 Inclusion of older adults (>55 years) ✓3,59,60 ✓10,11,12 ✓15,18,21,25,27,28,30,39,67,68 Inclusion of people of color and/or other ethnicities ✓3,4,59-
Slide 17: Ann Herbst, Young People in Recovery
17 Ann Herbst Executive Director Young People in Recovery
Slide 18: reSET Indications for Use
18 • reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. • reSET is indicated as a 12-week (90 day) prescription-o
Slide 19: reSET Data Overview
19 reSET Data Overview Payor • In the 6 months pre-post following reSET prescription:5 o 50% reduction in total hospitalizations o 45% reduction in emergency department visits o 56% reduction in inpatient admissions • Real-world evidence demonstrating reduced HCRU in the 6 months pre-post following
Slide 20: reSET pivotal trial outcomes
20 62.3% (n=193) 76.2% (n=206) 3.2% (n=193) 16.1% (n=206) p = 0.0013 p = 0.0042 Abstinence (amongst all patients) Abstinence (amongst patients who were not abstinent at study start) Treatment Retention Treatment as Usual (TAU) = F2F counseling, or Reduced TAU + for 12 weeks • 399 patients with subst
Slide 21: reSET real-world healthcare cost reductions
21 -70 -20 Inpatient Admissions ED Visits Hospital Outpatient ICU Admissions Partial Hospitalizations Unique Hospital Encounters reSET has demonstrated real-world healthcare cost reductions • Real-world claims analysis of healthcare resource utilization in the 6 months pre- and post-reSET Rx • Data
Slide 22: reSET-O Indications for Use
22 • reSET-O is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who a
Slide 23: reSET-O Data Overview
23 Payor • Real world health economic data on >950 OUD patients: • Short-term: 62% reduction in inpatient stays and 20% reduction in ED visits over 6 months12 • Long-term: 46% reduction in hospitalizations and >30% reduction in ICU stays compared to controls over 9 months13 • Durable: reSET-O saved
Slide 24: reSET-O real-world outcomes comparable to RCT outcomes
24 reSET has demonstrated real-world clinical outcomes comparable to RCT outcomes Analyses of “Abstinence” for each group: * Missing Data Removed: No positive UDS and/or self-reported use over the final 4 weeks of the 12- week reSET-O® prescription (weeks 9-12); Patients without any data (UDS or sel
Slide 25: reSET-O real-world engagement
25 reSET has demonstrated compelling real-world engagement This data does not derive from a head-to-head study, it is a comparison of 3 publicly available data sets 25 • Real-world observational evaluation of an all-comer population of patients who redeemed a 12-week prescription for reSET-O • Data
Slide 26: Durable healthcare cost reductions in Medicaid patients
26 Outcomes in Medicaid Patients:• Real world case-control analysis of healthcare resource utilization in the 12 months following reSET-O Rx • All patients: Data from 901 patients who utilized reSET and 978 control patients • Medicaid patients: Data from 666 patients who utilized reSET and 640 contr
Slide 27: Near-term and durable clinical and health economic outcomes
27 reSET demonstrates near-term and durable clinical and health economic outcomes $2,385 $2,600 2,791 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 6 month 9 month 12 month reSET-O HEOR Cost Savings over Time reSET-O $3,832 Medicaid Savings n = 351 n = 508 n = 1879 12 13 14
Slide 28: Somryst Indications for Use
28 • Somryst is a prescription-only digital therapeutic intended to provide a neurobehavioral intervention (CBT-I) to patients 22 years of age and older with chronic insomnia • Somryst treats patients with chronic insomnia by improving a patient’s insomnia symptoms re. Indications for Use Please see
Slide 29: Somryst Data Overview
29 reSET Data Overview †Somryst or Sleep Healthy Using the Internet (SHUTi) studies Payor • In the 24 months following Somryst initiation, there was a -$2,059 cost difference per patient17 • In the 24 months following Somryst initiation17: o 53% reduction in emergency department services o 21% reduc
Slide 30: Somryst pivotal trial outcomes (1/2)
30 pivotal trial outcomes (1/2) • Two randomized controlled trials that evaluated >1400 adults with chronic insomnia • Patients utilized the product for 9 weeks, consisting of 6 treatment modules (cores) • Data collected: o FDA-reviewed endpoint (Insomnia Severity Index) o Sleep Onset Latency (SOL):
Slide 31: Somryst pivotal trial outcomes (2/2)
31 pivotal trial outcomes (2/2) • Two randomized controlled trials that evaluated >1400 adults with chronic insomnia • Patients utilized the product for 9 weeks, consisting of 6 treatment modules (cores) • Data collected: o FDA-reviewed endpoint (Insomnia Severity Index) o Sleep Onset Latency (SOL):
Slide 32: Patient engagement in the real world
32 patient engagement in the real world IS I S co re ISI Score O U T C O M E S 18,19,71-73 % o f p at ie n ts ac ti ve Patient Engagement S O L S co re Sleep Onset Latency W A S O S co re Wake After Sleep Onset R E A L - W O R L D S T U D Y D E S I G N 18,19,71-73 • 7,414 patients utilized Somryst i
Slide 33: Somryst 24-month real-world health economic data
33 Cost difference after accounting for change in all categories of HCRU; Incidence and IRR are evaluated from a repeated measures (i.e., pre- and post-index for each patient) negative binomial model of count of stays/visits, with an offset for the number of days in each period. Reduction in emergen
Slide 34: Robust data set
34 reSET has a robust data set 44 Studies† • 2 RCTs used for FDA submission (>1400 patients)15,16,70 • Real world health economic study over 24 months (>$2,000 cost savings)17 • Real world evaluations across a total of (>8,000 patients)18,19,71-73 • Studies targeted relevant disease , underserved po
Slide 35: Clinical and cost data drives use and reimbursement
35 We believe Pear’s commercial progress is catalyzed by clinical and cost data which drives use and reimbursement Product Randomized Controlled Trials Real-World Clinical and Health Economic reSET3-6 ✓ 2 RCTs in >1,000 patients ✓ 6-month HCRU data in 100 patients reSET-O7-14 ✓ 3 RCTs in >450 patien
Slide 36: Questions
36 Questions
Slide 37: Agenda
37 Agenda Topic Time • Introduction to Pear Therapeutics 20 minutes • Medical: Clinical Data and Evidence 60 minutes • Market Access: Payment Infrastructure 60 minutes • Wrap Up 10 minutes
Slide 38: Dr. Trey Causey, Crossroads Treatment Centers
38 Dr. Trey Causey Chief Medical Officer Crossroads Treatment Centers
Slide 39: Why are we here?
39 Why are we here? Why do we care about data? Why do we care about market access? • 40M+ people suffer from addiction1 • Overdose rates have eclipsed 100,000 people per year2 • 30M+ people suffer from chronic insomnia3 • 30% of people using sleeping pills are addicted to them4 • Proves our products
Slide 40: Access pathways across major patient populations
40 Commercial State Federal Patient Populations Employer-insured and Self- insured Medicaid-insured and Uninsured Medicare, VA, and DoD Benefit Type Pharmacy, DME or Access Agreements Pharmacy, DME or Access Agreements Pharmacy, DME or Access Agreements reSET patient population ++ ++ ++ reSET-O pati
Slide 41: PDTs utilize existing coding frameworks
41 Granted upon application to CMS • HCPCS (Healthcare Common Procedure Coding System) • Products • Paid via medical benefit (i.e., Durable Medical Equipment) • CPT (Current Procedural Terminology) • Physician services • Paid via medical benefit (i.e., fee schedules) PDTs, like other therapy classes
Slide 42: PDT coding framework developing like other product classes
42 Product Reimbursement Clinician Reimbursement PDTs • NDC (pharmacy) • HCPCS (medical) • RTM CPT codes (medical) Injection and Infusion Services • NDC (pharmacy) • Injection and Infusion CPT codes (medical) Continuous Glucose Monitoring (CGM) • NDC (pharmacy) • HCPCS (medical) • Continuous Glucose
Slide 43: Growing set of codes for products and clinician time
43 • NDC-like (pharmacy) • HCPCS (medical) • CPT (medical) • NDC • reSET: 96439-0011-01 • reSET-O: 96439-0021-01 • Somryst: 96439-0030-01 • HCPCS • A9291 • RTM CPT Codes • 98975 • 98980 • 98981 PDTs have a growing set of codes for both products and clinician time
Slide 44: Payors can now utilize various access pathways
44 Payors can now utilize various access pathways Access Agreements Pharmacy Medical (via DME) Coding Both Modified UDI into NDC-like code HCPCS A9291 Billing Direct Pharmacy DME Supplier Time to process Minutes Minutes to days Days to weeks Payment Volume and/or Value-Based Rebate Volume and/or Val
Slide 45: Opportunities with large national and regional payors
45 Pear’s real-world data and emerging coding framework enable more opportunities with large national / regional payors Book of Business Relevant Business Units Available Opportunities Commercial • PBM • Health Plan • Employers • Value based contracts facilitated through PBMs • Scalable access agree
Slide 46: Government affairs activities driving patient access
46 Federal Government Momentum • Medicare Coverage via Federal Legislation8 • Medicare Coverage via HCPCS Workgroup9 Government affairs activities are driving for patient access Access to Prescription Digital Therapeutics Act of 20221 Original Sponsors: • U.S. Senators Shelley Moore Capito (R-W.Va.)
Slide 47: Access agreements with states and multi-year funding
47 Access agreements with states can augment Medicaid coverage using multi-year funding sources • Federal grants totaling over $20B annually flow into states through various vehicles12 • Settlement funds from class action lawsuits are still being settled and are beginning to flow to states (~$4.5B a
Slide 48: PDTs have a growing set of codes
48 PDTS have a growing set of codes for both products and clinician time • NDC-like (pharmacy) • HCPCS (medical) • CPT (medical) • NDC • reSET: 96439-0011-01 • reSET-O: 96439-0021-01 • Somryst: 96439-0030-01 • HCPCS • A9291 • RTM CPT Codes • 98975 • 98980 • 98981
Slide 49: CPT codes may provide payment to physicians
49 CPT codes may provide payment to physicians for certain services they provide around PDTs What do the RTM CPT codes cover? • Certain services related to remote monitoring of therapy adherence and therapy response (including CBT services) • Billing for Monitoring and Adherence of remote digital CB
Slide 50: Dr. Scott Whittle, Former Medical Director, Intermountain Healthcare
50 Dr. Scott Whittle Former Medical Director Intermountain Healthcare
Slide 51: Pear is committed to providing PDTs at scale
51 Total Prescriptions Fulfillment Rate Payment Rate Average Selling Price (ASP) CPT Codes RECENT MILESTONES EMR Integration Real-World Health Economic Evidence State and Federal Legislation HCPCS Code Access Agreements Pear is committed to providing PDTs at scale
Slide 52: Questions
52 Questions
Slide 53: Agenda
53 Agenda Topic Time • Introduction to Pear Therapeutics 20 minutes • Medical: Clinical Data and Evidence 60 minutes • Market Access: Payment Infrastructure 60 minutes • Wrap Up 10 minutes
Slide 54: Copyright 2022, Pear Therapeutics
54 Copyright 2022, Pear Therapeutics, Inc. All rights reserved.
Slide 55: Introduction to Pear Therapeutics: References
55 Introduction to Pear Therapeutics 1. https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf 2. https://www.ajmc.com/view/insomnia-overview-epidemiology-pathophysiology-diagnosis-and-monitoring-and-nonpharmacologic-therapy 3. Total Pr
Slide 56: References: Medical: Clinical Data and Evidence
56 References Medical: Clinical Data and Evidence 1. https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf 2. https://www.ajmc.com/view/insomnia-overview-epidemiology-pathophysiology-diagnosis-and-monitoring-and-nonpharmacologic-therap
Slide 57: References: Medical: Clinical Data and Evidence
57 References Medical: Clinical Data and Evidence 15. Ritterband LM, Thorndike FP, Ingersoll KS, et al. (2017): Effect of a Web-Based Cognitive Behavior Therapy for Insomnia Intervention With 1-Year Follow-up: A Randomized Clinical Trial. JAMA Psychiatry. 74(1):68–75. doi:10.1001/jamapsychiatry.2016
Slide 58: References: Medical: Clinical Data and Evidence
58 References Medical: Clinical Data and Evidence 26. Moloney ME, Dunfee M, Rutledge M, Schoenberg N. Evaluating the Feasibility and Acceptability of Internet-Based Cognitive Behavioral Therapy for Insomnia in Rural Women. Women’s Health Reports. 2020; 1:114-122. doi:10.1089/whr.2020.0053 27. Mairea
Slide 59: References: Medical: Clinical Data and Evidence
59 References Medical: Clinical Data and Evidence 37. Vedaa, Ø., Hagatun, S., Kallestad, H., Pallesen, S., Smith, O. R. F., Thorndike, F. P., Ritterband, L. M., Sivertsen, B. (2019). Long-term effects of an unguided online cognitive behavioral therapy for chronic insomnia. Journal of Clinical Sleep
Slide 60: References: Medical: Clinical Data and Evidence
60 References Medical: Clinical Data and Evidence 47. Ritterband, L. M., Thorndike, F. P., Gonder-Frederick, L., Magee, J. C., Bailey, E., Saylor, D. K., & Morin, C. M. (2009). Efficacy of an Internet-based behavioral intervention for adults with insomnia. Archives of General Psychiatry, 66(7), 692-
Slide 61: References: Medical: Clinical Data and Evidence
61 References Medical: Clinical Data and Evidence 56. Ritterband, L. M. (2010). Commentary: Can cognitive behavioral therapy of insomnia be effectively provided via an Internet-based program? Best of Sleep Medicine 2010: An Annual Collection of Scientific Literature (COMMENTARY) 57. Thorndike, F. P.
Slide 62: References: Medical: Clinical Data and Evidence
62 References Medical: Clinical Data and Evidence 72. Thorndike FP, Gerwien R, Maricich YA, Luderer HF, Enman NM, Xiong R, Edington S, Ritterband L. Evidence From Real-World Users of a Digital Therapeutic for Insomnia. 173rd Annual Meeting of the American Psychiatric Association; April 25-29, 2020;
Slide 63: References: Market Access: Payment Infrastructure
63 Market Access: Payment Infrastructure 1. https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf 2. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2021/20211117.htm 3. https://www.ajmc.com/view/insomnia-overview-epidemiology-p
Slide 64: References: Market Access: Payment Infrastructure
64 Market Access: Payment Infrastructure 18. https://mainecare.maine.gov/Provider%20Fee%20Schedules/Forms/Publication.aspx?RootFolder=%2FProvider%20Fee%20Schedules%2FMaineCare %20UCR&FolderCTID=0x012000264D1FBA0C2BB247BF40A2C571600E81&View=%7B69CEE1D4%2DA5CC%2D4DAE%2D93B6%2D72A66DE366E0%7D 19. http: